Eckelman Brendan P. 13D and 13G filings for Inhibrx Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:12 pm Sale | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Eckelman Brendan P. | 2,397,219 5.100% | -352,734 (-12.83%) | Filing |
| 2021-02-12 4:38 pm Purchase | 2020-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | Eckelman Brendan P. | 2,749,953 7.300% | 2,749,953 (New Position) | Filing |